Scarica l'app Stockscreener
2.44
2.95%
0.07
Precedente Chiudi:
$2.37
Aprire:
$2.39
Volume 24 ore:
678.05K
Relative Volume:
0.94
Capitalizzazione di mercato:
$196.59M
Reddito:
$52.74M
Utile/perdita netta:
$-6.60M
Rapporto P/E:
-28.88
EPS:
-0.0845
Flusso di cassa netto:
$-13.63M
1 W Prestazione:
+5.17%
1M Prestazione:
+23.86%
6M Prestazione:
+17.87%
1 anno Prestazione:
+64.86%
Intervallo 1D:
$2.33
$2.45
Intervallo di 1 settimana:
$2.2562
$2.45
Portata 52W:
$1.36
$3.19
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Nome
Protalix BioTherapeutics Inc.
Settore
Industria
Telefono
972 4 988 9488
Indirizzo
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.44 | 196.59M | 52.74M | -6.60M | -13.63M | -0.0845 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-17 | Reiterato | Rodman & Renshaw | Buy |
| 2016-04-04 | Iniziato | Rodman & Renshaw | Buy |
| 2015-04-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2014-11-12 | Reiterato | R. F. Lafferty | Buy |
| 2014-01-24 | Iniziato | R. F. Lafferty | Buy |
| 2012-05-02 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | Reiterato | Oppenheimer | Outperform |
| 2012-04-30 | Downgrade | Auriga | Buy → Hold |
| 2011-10-13 | Iniziato | Morgan Joseph | Hold |
| 2011-03-17 | Downgrade | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | Reiterato | Oppenheimer | Outperform |
| 2010-10-14 | Reiterato | UBS | Buy |
| 2009-12-02 | Reiterato | Hapoalim | Outperform |
| 2009-09-22 | Iniziato | Canaccord Adams | Buy |
| 2009-09-02 | Iniziato | Hapoalim | Outperform |
| 2008-12-01 | Reiterato | Oppenheimer | Outperform |
| 2008-03-11 | Iniziato | UBS | Buy |
| 2007-11-20 | Iniziato | CIBC Wrld Mkts | Sector Outperform |
Mostra tutto
Protalix BioTherapeutics Inc. Borsa (PLX) Ultime notizie
ETFs Investing in Protalix Biotherapeutics, Inc. Stocks - TradingView
PLXProtalix BioTherapeutics Inc Volatility & Greeks - Finviz
Price to book forward of Protalix Biotherapeutics, Inc. – SWB:PBDA - TradingView
Price to sales forward of Protalix BioTherapeutics, Inc. (DE) – AMEX:PLX - TradingView
Price to sales forward of Protalix Biotherapeutics, Inc. – SWB:PBDA - TradingView
Protalix BioTherapeutics, Inc. (PLX) Investigation: Bronstein, Ge - The National Law Review
Price to earnings forward of Protalix BioTherapeutics, Inc. (DE) – AMEX:PLX - TradingView
Enterprise value to EBIT forward of Protalix BioTherapeutics, Inc. (DE) – AMEX:PLX - TradingView
Price to earnings forward of Protalix Biotherapeutics, Inc. – FWB:PBDA - TradingView
Enterprise value to EBIT forward of Protalix Biotherapeutics, Inc. – FWB:PBDA - TradingView
Enterprise value to revenue forward of Protalix BioTherapeutics, Inc. (DE) – AMEX:PLX - TradingView
Enterprise value to EBITDA forward of Protalix Biotherapeutics, Inc. – FWB:PBDA - TradingView
Enterprise value to revenue forward of Protalix Biotherapeutics, Inc. – FWB:PBDA - TradingView
PBDA Forecast — Price Target — Prediction for 2027 - TradingView
Protalix Shareholders Approve Directors, Compensation and Incentive Plan - The Globe and Mail
Protalix BioTherapeutics, Inc. 8-K Filing Details: Company Information, Governance, and Plan Definitions (June 25, 2026) - Minichart
Protalix (NYSE: PLX) investors approve directors, pay and expanded stock plan - Stock Titan
Protalix Biotherapeutics, Inc. Actuals & Estimates (AMEX:PLX) - TradingView
Spotlight On 3 Penny Stocks With Market Caps Under $2B - simplywall.st
Protalix Biotherapeutics Inc (PLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PLX Q1 2026 Earnings: Significant Earnings Beat Driven by Key Milestone EventsConsensus Miss Rate - dars.gov.et
Protalix Biotherapeutics Inc (PLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Protalix Biotherapeutics Inc (PLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Protalix Biotherapeutics Inc (PLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Protalix Biotherapeutics Inc (PLX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Protalix Biotherapeutics Inc (PLX) Institutional Confidence - TradingKey
Protalix Biotherapeutics Inc (PLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Protalix Biotherapeutics Inc (PLX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Protalix Biotherapeutics Inc (PLX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Protalix BioTherapeutics (PLX) Holds Steady at $2.08 After Minimal DeclinePercent Below MA - newsline.com
PLX Q1 2026 Earnings: EPS Rockets Past Estimates, Stock Edges LowerGuidance vs Actual - newsline.com
Protalix BioTherapeutics (PLX) Holds Near Key Support After Mild DeclineZero Lag EMA - newsline.com
Protalix BioTherapeutics (PLX) Holds Near Support After Modest DeclinePut Dominated - thelegaladvocate.com
H.C. Wainwright Maintains Protalix Biotherapeutics(PLX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Protalix BioTherapeutics (PLX) Rises 1.43% as Biotech Stock Tests Key ResistancePrice Gap Fill - The Legal Advocate
3 Penny Stocks With Market Caps Larger Than $100M To Consider - Sahm
PLX Q1 2026 Earnings: Massive EPS Surprise as Protalix BioTherapeutics Reports Strong ProfitabilityRevenue Growth Outlook - The Legal Advocate
PLX Stock Price, Quote & Chart | PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) - ChartMill
Protalix Highlights Elfabrio Dosing Approvals and Growth Plans - TipRanks
Protalix BioTherapeutics Advances Rare Disease Treatments with Elfabrio® and PRX-115, Achieves Key Regulatory and Pipeline Milestones - Minichart
Protalix BioTherapeutics (PLX) posts new May 2026 corporate presentation for investors - Stock Titan
Protalix BioTherapeutics appoints Gilad Mamlok as CFO - MSN
Protalix BioTherapeutics (PLX) Q1 2026 8-K: EPS Not Disclosed, R - GuruFocus
Protalix reaffirms $78M-$83M 2026 revenue outlook following $25M Elfabrio milestone - MSN
Protalix Q1 Call: Milestone-Fueled Profit, Bold Targets - The Globe and Mail
PLX: Chiesi milestone received - MSN
PLX: Chiesi Milestone Received - Yahoo Finance
Protalix BioTherapeutics 1Q Rev $33.8M >PLX - Moomoo
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2026 Earnings Call Transcript - Insider Monkey
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results - Sahm
Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ... By GuruFocus - Investing.com Canada
Protalix BioTherapeutics Inc. Azioni (PLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):